The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Bristol Myers to Buy Precision Oncology Co.

Streetwise Reports (06/03/2022)

Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share.

Tags: Biotechnology / Pharmaceuticals

Precision Oncology Co. Signs $1.325B Licensing Deal

Streetwise Reports (06/02/2022)

Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved.

Tags: Biotechnology / Pharmaceuticals

Important Data for COVID Drug Candidate Due This Month

Research Report

(06/02/2022)

The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Cancer Patients Have Partial Response With Drug

Research Report

(05/28/2022)

The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Cancer Targeting Drug Better Tolerated Than Others

Research Report

(05/27/2022)

A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report.

Tags: Biotechnology / Pharmaceuticals

50% Revenue Growth Expected This Year for Biopharma Co.

Research Report

(05/26/2022)

The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Target Price on Drug Co. Suggests Possible Huge Returns

Research Report

(05/25/2022)

Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Innoviva Buys Remaining Shares in Advanced Antibiotic Co.

Streetwise Reports (05/23/2022)

Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share.

Tags: Biotechnology / Pharmaceuticals

H2/22 Slated to Be Catalyst Rich for Pharma Co.

Research Report

(05/21/2022)

Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs.

Tags: Biotechnology / Pharmaceuticals

New Improved Drug Expected to Get FDA Approval Next Month

Research Report

(05/20/2022)

Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.

Tags: Biotechnology / Pharmaceuticals

US Pharma Co. Granted FDA Approval for IV Smallpox Drug

Streetwise Reports (05/20/2022)

SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox.

Tags: Biotechnology / Pharmaceuticals

Firm Reports Encouraging Trial Results in Cystinosis

Research Report

(05/19/2022)

New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.

Tags: Biotechnology / Pharmaceuticals

EU Co. Secures Smallpox Vaccine Order to Target Monkeypox

Streetwise Reports (05/19/2022)

Shares of Danish vaccine company Bavarian Nordic A/S traded 70% higher after the company advised that it had secured a contract for its IMVANEX® smallpox vaccine from an undisclosed country in Europe for use in addressing newly confirmed cases of monkeypox.

Tags: Biotechnology / Pharmaceuticals

Coverage Launched on Co. in Alzheimer's Drug Space

Research Report

(05/17/2022)

This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.

Tags: Biotechnology / Pharmaceuticals

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Research Report

(05/15/2022)

Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. to Launch Two Clinical Trials This Year

Research Report

(05/14/2022)

Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm

Streetwise Reports (05/13/2022)

Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer.

Tags: Biotechnology / Pharmaceuticals

First Results From Biotech Co.'s Lymphoma Program Are Impressive

Research Report

(05/13/2022)

This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Pfizer Offers $11.6B to Buy Biopharma Co.

Streetwise Reports (05/10/2022)

Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M

Streetwise Reports (05/05/2022)

Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver.

Tags: Biotechnology / Pharmaceuticals

Analyst Says Avivagen Is a Strong Buy

Contributed Opinion

Clive Maund (05/05/2022)

With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy.

Tags: NutraceuticalsBiotechnology / Pharmaceuticals

Pilot Launch of VLN Cigarettes in Progress

Research Report

(05/03/2022)

These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.

Tags: AgricultureBiotechnology / Pharmaceuticals

Biotech Co. Advances COVID-19 Vaccines Toward Approval

Research Report

(05/01/2022)

They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Could a New Prescription Drug Treat This Common Ailment?

Research Report

(04/27/2022)

The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.

Tags: Biotechnology / Pharmaceuticals